Correlation Engine 2.0
Clear Search sequence regions


  • 8 oh (1)
  • adult (1)
  • anti hiv agents (2)
  • cyclopropanes (2)
  • CYP2B6 (14)
  • efavirenz (4)
  • female (1)
  • humans (1)
  • linear model (2)
  • micro rnas (10)
  • P 450 (2)
  • plasma (3)
  • protein human (1)
  • race (1)
  • volunteers (1)
  • young adult (1)
  • Sizes of these terms reflect their relevance to your search.

    The CYP2B6 gene is highly polymorphic and its activity shows wide interindividual variability. However, substantial variability in CYP2B6 activity remains unexplained by the known CYP2B6 genetic variations. Circulating, cell-free micro RNAs (miRNAs) may serve as biomarkers of hepatic enzyme activity. CYP2B6 activity in 72 healthy volunteers was determined using the disposition of efavirenz as a probe drug. Circulating miRNA expression was quantified from baseline plasma samples. A linear model consisting of the effects of miRNA expression, genotype-determined metabolizer status, and demographic information was developed to predict CYP2B6 activity. Expression of 2,510 miRNAs were quantified out of which 7 miRNAs, together with the CYP2B6-genotypic metabolizer status and demographics, was shown to be predictive markers for CYP2B6 activity. The reproducibility of the model was evaluated by cross-validation. The average Pearson's correlation (R) between the predicted and observed maximum plasma concentration (Cmax ) ratios of efavirenz and its metabolite-8-OH efavirenz using the linear model with all features (7 miRNA + metabolizer status + age + sex + race) was 0.6702. Similar results were also observed using area under the curve (AUC) ratios (Pearson correlation's R = 0.6035). Thus, at least 36% (R2 ) of the variability of in vivo CYP2B6 activity was explained using this model. This is a significant improvement over the models using only the genotype-based metabolizer status or the demographic information, which explained only 6% or less of the variability of in vivo CYP2B6 activity. Our results, therefore, demonstrate that circulating plasma miRNAs can be valuable biomarkers for in vivo CYP2B6 activity. © 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

    Citation

    Joseph Ipe, Rudong Li, Ingrid F Metzger, Jessica Bo Li Lu, Brandon T Gufford, Zeruesenay Desta, Yunlong Liu, Todd C Skaar. Circulating miRNAs as Biomarkers for CYP2B6 Enzyme Activity. Clinical pharmacology and therapeutics. 2021 Feb;109(2):485-493

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 32772362

    View Full Text